Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
Clinical trial NCT02519270 · TERMINATED
Trial details
- NCT number
- NCT02519270
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-01
- Primary completion
- 2018-05-04
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.